HRP20190937T1 - Protutijela za neutraliziranje jcv - Google Patents
Protutijela za neutraliziranje jcv Download PDFInfo
- Publication number
- HRP20190937T1 HRP20190937T1 HRP20190937TT HRP20190937T HRP20190937T1 HR P20190937 T1 HRP20190937 T1 HR P20190937T1 HR P20190937T T HRP20190937T T HR P20190937TT HR P20190937 T HRP20190937 T HR P20190937T HR P20190937 T1 HRP20190937 T1 HR P20190937T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- acid sequence
- antibody
- seq
- variable domain
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 3
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 3
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Monoklonsko protutijelo koje neutralizira izolirani virus JC, usmjereno protiv proteina VP1 iz kapside JCV (JCV-VP1), naznačeno time što navedeno monoklonsko protutijelo ima:
varijabilnu domenu teškog lanca koja sadrži aminokiselinski slijed CDR1 istovjetan aminokiselinskom slijedu SEQ ID NO: 31, aminokiselinski slijed CDR2 istovjetan aminokiselinskom slijedu SEQ ID NO: 35, te aminokiselinski slijed CDR3 istovjetan aminokiselinskom slijedu SEQ ID NO: 9; i
varijabilnu domenu lakog lanca koja sadrži aminokiselinski slijed CDR3 istovjetan aminokiselinskom slijedu SEQ ID NO: 17, aminokiselinski slijed CDR2 istovjetan aminokiselinskom slijedu SEQ ID NO: 3, i aminokiselinski slijed CDR3 istovjetan aminokiselinskom slijedu SEQ ID NO: 4.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je najmanje jedan aminokiselinski slijed okosničnog područja varijabilne domene teškog lanca najmanje 90 % istovjetan najmanje jednom odgovarajućem aminokiselinskom slijedu okosničnog područja aminokiselinskog slijeda varijabilne domene teškog lanca istovjetnog aminokiselinskom slijedu SEQ ID NO: 20.
3. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo ima aminokiselinski slijed varijabilne domene teškog lanca koji je najmanje 90 % istovjetan aminokiselinskom slijedu SEQ ID NO: 20.
4. Protutijelo u skladu s patentnim zahtjevom 3, naznačeno time što navedeno protutijelo ima aminokiselinski slijed varijabilne domene teškog lanca istovjetan aminokiselinskom slijedu SEQ ID NO: 20.
5. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je najmanje jedan aminokiselinski slijed okosničnog područja varijabilne domene lakog lanca najmanje 90 % istovjetan najmanje jednom odgovarajućem aminokiselinskom slijedu okosničnog područja aminokiselinskog slijeda varijabilne domene lakog lanca istovjetnog aminokiselinskom slijedu SEQ ID NO: 15.
6. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo ima aminokiselinski slijed varijabilne domene lakog lanca koji je najmanje 90 % istovjetan aminokiselinskom slijedu SEQ ID NO: 15.
7. Protutijelo u skladu s patentnim zahtjevom 6, naznačeno time što navedeno protutijelo ima aminokiselinski slijed varijabilne domene lakog lanca istovjetan aminokiselinskom slijedu SEQ ID NO: 15.
8. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što navedeno protutijelo ima aminokiselinski slijed varijabilne domene teškog lanca istovjetan aminokiselinskom slijedu SEQ ID NO: 20 i aminokiselinski slijed varijabilne domene lakog lanca istovjetan aminokiselinskom slijedu SEQ IDNO: 15.
9. Protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što je protutijelo kimerno protutijelo.
10. Protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što protutijelo ima Fc područje iz IgG1.
11. Protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što je namijenjeno upotrebi u postupku liječenja subjekta s jednim ili više znakova ili simptoma progresivne multifokalne leukoencefalopatije (PML) ili koji ima PML.
12. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što protutijelo prolazi kroz krvno-moždanu barijeru.
13. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 11 ili 12, naznačeno time što liječenje rezultira smanjenjem virusnog opterećenja, poboljšanjem na EDSS ljestvici, poboljšanjem na Kamofskvjevoj ljestvici, poboljšanim MRI skeniranjem ili poboljšanjem kognicije.
14. Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 11-13, naznačeno time što se subjekt podvrgava, ili je podvrgavan, imunoterapijskom liječenju.
15. Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 11-14, naznačeno time što je subjekt imunosno oslabljen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613214P | 2012-03-20 | 2012-03-20 | |
| PCT/US2013/031842 WO2013142299A1 (en) | 2012-03-20 | 2013-03-15 | Jcv neutralizing antibodies |
| EP13765090.9A EP2828284B1 (en) | 2012-03-20 | 2013-03-15 | Jcv neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190937T1 true HRP20190937T1 (hr) | 2019-10-04 |
Family
ID=49223243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190937TT HRP20190937T1 (hr) | 2012-03-20 | 2019-05-21 | Protutijela za neutraliziranje jcv |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9567392B2 (hr) |
| EP (2) | EP2828284B1 (hr) |
| CA (1) | CA2867902C (hr) |
| CY (1) | CY1121856T1 (hr) |
| DK (1) | DK2828284T3 (hr) |
| ES (1) | ES2731757T3 (hr) |
| HR (1) | HRP20190937T1 (hr) |
| HU (1) | HUE044838T2 (hr) |
| LT (1) | LT2828284T (hr) |
| PL (1) | PL2828284T3 (hr) |
| PT (1) | PT2828284T (hr) |
| RS (1) | RS58910B1 (hr) |
| SI (1) | SI2828284T1 (hr) |
| TR (1) | TR201909801T4 (hr) |
| WO (1) | WO2013142299A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2828284B1 (en) | 2012-03-20 | 2019-05-08 | Biogen MA Inc. | Jcv neutralizing antibodies |
| ES2706173T3 (es) | 2012-03-20 | 2019-03-27 | Biogen Ma Inc | Anticuerpos de neutralización de JCV |
| ITTO20120570A1 (it) * | 2012-06-27 | 2013-12-28 | Pomona Ricerca Srl | Anticorpo monoclonale diretto contro il virus jc |
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| CN111417651B (zh) | 2017-12-01 | 2023-09-29 | 诺华股份有限公司 | 多瘤病毒中和抗体 |
| JP2022537544A (ja) * | 2019-06-19 | 2022-08-26 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｊｃウイルスに対するモノクローナル抗体 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| NZ261259A (en) | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
| AU687790B2 (en) | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| SG170749A1 (en) | 2005-12-20 | 2011-05-30 | Sbi Biotech Co Ltd | Anti-ilt7 antibody |
| JP2009536641A (ja) | 2006-05-31 | 2009-10-15 | ハンワ ケミカル コーポレイション | Ｖｃａｍ−１特異的モノクローナル抗体 |
| US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
| PT2308514E (pt) * | 2007-03-23 | 2013-09-06 | To Bbb Holding B V | Conjugados para a administração orientada de medicamentos através da barreira hematoencefálica |
| WO2009023386A2 (en) | 2007-07-06 | 2009-02-19 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
| CN102076716A (zh) | 2008-06-25 | 2011-05-25 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 抑制TNFα的稳定和可溶的抗体 |
| WO2010090757A1 (en) | 2009-02-05 | 2010-08-12 | Biogen Idec Ma Inc. | Methods for the detection of jc polyoma virus |
| WO2010129959A1 (en) | 2009-05-08 | 2010-11-11 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the prevention and treatment of lupus nephritis using anti-dsdna germline antibodies |
| EP2316481A1 (en) | 2009-10-30 | 2011-05-04 | Biomay Ag | Pharmaceutical composition for the treatment and prevention of a rhinovirus infection |
| EP2828284B1 (en) | 2012-03-20 | 2019-05-08 | Biogen MA Inc. | Jcv neutralizing antibodies |
| ES2706173T3 (es) | 2012-03-20 | 2019-03-27 | Biogen Ma Inc | Anticuerpos de neutralización de JCV |
-
2013
- 2013-03-15 EP EP13765090.9A patent/EP2828284B1/en active Active
- 2013-03-15 RS RS20190730A patent/RS58910B1/sr unknown
- 2013-03-15 CA CA2867902A patent/CA2867902C/en active Active
- 2013-03-15 ES ES13765090T patent/ES2731757T3/es active Active
- 2013-03-15 TR TR2019/09801T patent/TR201909801T4/tr unknown
- 2013-03-15 PL PL13765090T patent/PL2828284T3/pl unknown
- 2013-03-15 PT PT13765090T patent/PT2828284T/pt unknown
- 2013-03-15 EP EP19172368.3A patent/EP3575311A1/en not_active Withdrawn
- 2013-03-15 SI SI201331459T patent/SI2828284T1/sl unknown
- 2013-03-15 DK DK13765090.9T patent/DK2828284T3/da active
- 2013-03-15 WO PCT/US2013/031842 patent/WO2013142299A1/en active Application Filing
- 2013-03-15 LT LTEP13765090.9T patent/LT2828284T/lt unknown
- 2013-03-15 US US14/386,262 patent/US9567392B2/en active Active
- 2013-03-15 HU HUE13765090 patent/HUE044838T2/hu unknown
-
2019
- 2019-05-21 HR HRP20190937TT patent/HRP20190937T1/hr unknown
- 2019-07-30 CY CY20191100809T patent/CY1121856T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1121856T1 (el) | 2020-07-31 |
| DK2828284T3 (da) | 2019-06-11 |
| US20150050271A1 (en) | 2015-02-19 |
| TR201909801T4 (tr) | 2019-07-22 |
| EP2828284B1 (en) | 2019-05-08 |
| HUE044838T2 (hu) | 2019-11-28 |
| WO2013142299A1 (en) | 2013-09-26 |
| EP2828284A1 (en) | 2015-01-28 |
| PT2828284T (pt) | 2019-06-17 |
| US9567392B2 (en) | 2017-02-14 |
| EP3575311A1 (en) | 2019-12-04 |
| RS58910B1 (sr) | 2019-08-30 |
| CA2867902A1 (en) | 2013-09-26 |
| LT2828284T (lt) | 2019-08-26 |
| EP2828284A4 (en) | 2015-07-22 |
| ES2731757T3 (es) | 2019-11-18 |
| SI2828284T1 (sl) | 2019-10-30 |
| CA2867902C (en) | 2023-09-26 |
| PL2828284T3 (pl) | 2019-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190937T1 (hr) | Protutijela za neutraliziranje jcv | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| HRP20201634T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 | |
| HRP20201505T1 (hr) | Široko neutralizirajuća anti-hiv protutijela | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| JP2015504421A5 (hr) | ||
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| JP2016063812A5 (hr) | ||
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2018121657A5 (hr) | ||
| HRP20190643T1 (hr) | Protutijela protiv dkk-1 | |
| HRP20230065T1 (hr) | Humanizirana protutijela koja prepoznaju alfa-sinuklein | |
| RU2020120613A (ru) | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2014533239A5 (hr) | ||
| JP2012501669A5 (hr) | ||
| RU2011116927A (ru) | Антитела против интерлейкина 17 (ил-17) человека и их применение | |
| HRP20230844T1 (hr) | Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
| RU2018112861A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| HRP20240005T1 (hr) | Multispecifični mutirani fab fragmenti protutijela | |
| RU2017137740A (ru) | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения | |
| JP2012254092A5 (hr) |